Last update 22 Apr 2025

Shenzhen Celconta Life Science Co., Ltd.

Private Company | Subsidiary Company|
2020|
Guangdong Sheng, China

Overview

Tags

Neoplasms
Skin and Musculoskeletal Diseases
CAR-T
Natural Killer Cell Therapies

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms3
Top 5 Drug TypeCount
CAR-T2
Natural Killer Cell Therapies1
Top 5 TargetCount
nectin-41
CLDN18.2(Claudin 18.2)1

Related

3
Drugs associated with Shenzhen Celconta Life Science Co., Ltd.
PANK-003
Target-
Mechanism-
Active Org.
Shenzhen Celconta Life Science Co., Ltd.
Originator Org.
Guangdong Xiankangda Biotechnology Co. Ltd.
Active Indication
Solid tumor
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
CT-225
Target
CLDN18.2
Mechanism
CLDN18.2 inhibitors
Active Org.
Shenzhen Celconta Life Science Co., Ltd.
Originator Org.-
Active Indication
CLDN18.2 positive Solid Tumors
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
XKDCT-293
Target
nectin-4
Mechanism
nectin-4 inhibitors
Active Org.
Shenzhen Celconta Life Science Co., Ltd.
Originator Org.
Shenzhen Celconta Life Science Co., Ltd.
Active Indication
Advanced breast cancer
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
3
Clinical Trials associated with Shenzhen Celconta Life Science Co., Ltd.
NCT06782425
/ RecruitingPhase 1
A Single-center, Single-arm, Dose-escalation Exploratory Clinical Trial of the Safety, Efficacy, and Pharmacokinetics of XKDCT225 (Targeting Claudin18.2-CAR-T) Cell Injectionin Claudin18.2-positive Advanced Solid Tumors
NCT06724835
/ RecruitingPhase 1
A Single-center, Single-arm, Dose-escalation Exploratory Clinical Trial of the Safety, Efficacy, and Pharmacokinetics of XKDCT293 (Nectin-4-CAR-T) in Nectin-4-positive Advanced Breast Cancer
NCT06897228
/ RecruitingPhase 1
A Single-center, Single-arm, Dose-escalation Exploratory Clinical Trial on the Safety and Efficacy of PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors
100 Clinical Results associated with Shenzhen Celconta Life Science Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Shenzhen Celconta Life Science Co., Ltd.
Login to view more data
100 Deals associated with Shenzhen Celconta Life Science Co., Ltd.
Login to view more data
100 Translational Medicine associated with Shenzhen Celconta Life Science Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1
3
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
XKDCT-293
 ( nectin-4 )		Advanced breast cancer
More
Phase 1
CT-225
 ( CLDN18.2 )		CLDN18.2 positive Solid Tumors
More
Phase 1
PANK-003
Solid tumor
More
Phase 1
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free